<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml>
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="0" size="22" family="Times" color="#000000"/>
	<fontspec id="1" size="8" family="Times" color="#000000"/>
	<fontspec id="2" size="7" family="Times" color="#000000"/>
<text top="23" left="55" width="517" height="33" font="0"><b>ENCODE DCC Antibody Validation Document</b></text>
<text top="77" left="48" width="81" height="12" font="1">Date of Submission</text>
<text top="347" left="39" width="41" height="12" font="1">Antibody </text>
<text top="359" left="39" width="52" height="12" font="1">Description: </text>
<text top="371" left="39" width="2" height="12" font="1"> </text>
<text top="485" left="84" width="61" height="12" font="1">Species Target</text>
<text top="521" left="84" width="90" height="12" font="1">Validation Method #1</text>
<text top="134" left="291" width="25" height="12" font="1">Email:</text>
<text top="134" left="48" width="27" height="12" font="1">Name:</text>
<text top="215" left="48" width="68" height="12" font="1">Antibody Name:</text>
<text top="215" left="300" width="29" height="12" font="1">Target:</text>
<text top="170" left="192" width="15" height="12" font="1">Lab</text>
<text top="249" left="183" width="44" height="12" font="1">Company/</text>
<text top="261" left="183" width="31" height="12" font="1">Source:</text>
<text top="485" left="300" width="53" height="12" font="1">Species Host</text>
<text top="300" left="336" width="50" height="12" font="1">Lot Number</text>
<text top="294" left="39" width="172" height="12" font="1">Catalog Number, database ID, laboratory </text>
<text top="306" left="39" width="2" height="12" font="1"> </text>
<text top="521" left="300" width="90" height="12" font="1">Validation Method #2</text>
<text top="555" left="84" width="50" height="12" font="1">Purification </text>
<text top="567" left="84" width="33" height="12" font="1">Method</text>
<text top="555" left="300" width="48" height="12" font="1">Polyclonal/ </text>
<text top="567" left="300" width="50" height="12" font="1">Monoclonal</text>
<text top="626" left="30" width="58" height="12" font="1">Reference (PI/</text>
<text top="638" left="30" width="49" height="12" font="1">Publication </text>
<text top="650" left="30" width="52" height="12" font="1">Information)</text>
<text top="674" left="28" width="294" height="12" font="1">Please complete the following for antibodies to histone modifications: </text>
<text top="687" left="28" width="205" height="11" font="2">if your specifications are not listed in the drop-down box,  </text>
<text top="697" left="28" width="155" height="11" font="2">please write-in the appropriate information</text>
<text top="728" left="30" width="59" height="12" font="1">Histone Name</text>
<text top="728" left="156" width="52" height="12" font="1">AA modified</text>
<text top="728" left="327" width="48" height="12" font="1">AA Position</text>
<text top="728" left="444" width="53" height="12" font="1">Modification</text>
<text top="419" left="39" width="29" height="12" font="1">Target </text>
<text top="431" left="39" width="52" height="12" font="1">Description: </text>
<text top="443" left="39" width="2" height="12" font="1"> </text>
<text top="599" left="165" width="51" height="12" font="1">Vendor URL:</text>
<text top="77" left="138" width="52" height="12" font="1">Jun 26, 2011</text>
<text top="359" left="94" width="418" height="12" font="1">epitope corresponding to amino acids 61-360 mapping near the N-terminus of SPT5 of human origin</text>
<text top="485" left="150" width="31" height="12" font="1">Human</text>
<text top="521" left="178" width="53" height="12" font="2">Western Blot</text>
<text top="134" left="326" width="182" height="12" font="1">Nathan_Lamarre-Vincent@hms.harvard.edu</text>
<text top="134" left="83" width="102" height="12" font="1">Nathan Lamarre-Vincent</text>
<text top="215" left="121" width="55" height="12" font="1"> SPT5 (H-300)</text>
<text top="215" left="339" width="25" height="12" font="1">hSpt5</text>
<text top="170" left="230" width="25" height="12" font="1">Struhl</text>
<text top="255" left="239" width="107" height="12" font="1">Santa Cruz Biotechnology</text>
<text top="485" left="361" width="27" height="12" font="1">Rabbit</text>
<text top="300" left="215" width="37" height="12" font="1">sc-28678</text>
<text top="521" left="395" width="89" height="12" font="2">Immunoprecipitation</text>
<text top="561" left="141" width="48" height="12" font="2">Protein A/G</text>
<text top="561" left="356" width="43" height="12" font="2">Polyclonal</text>
<text top="413" left="94" width="447" height="12" font="1">hSpt5 heterodimerizes with hSpt4 to form the DRB Sensitivity Inducing Factor (DSIF). DSIF play dual roles in </text>
<text top="425" left="94" width="452" height="12" font="1">elongation. First, in a conjunction with NELF, dephosphorylated state DSIF blocks RNA polymerase II (RNAPII) </text>
<text top="437" left="94" width="451" height="12" font="1">from shifting from early elongation to productive elongation.  Second, after phosphorylation DSIF continues </text>
<text top="449" left="94" width="445" height="12" font="1">to associate with elongating RNAPII to facilitate recruitment of factors required for processing of the mRNA.</text>
<text top="599" left="238" width="187" height="12" font="1">http://www.scbt.com/datasheet-28678-spt5-</text>
<text top="611" left="238" width="86" height="12" font="1">h-300-antibody.html</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="792" width="612">
<text top="146" left="52" width="57" height="12" font="1">Validation #1 </text>
<text top="158" left="52" width="34" height="12" font="1">Analysis</text>
<text top="661" left="50" width="143" height="12" font="1">Insert Validation Image (click here)</text>
<text top="152" left="125" width="310" height="12" font="1">Western blot analysis identified a major band at the correct size of ~121kD.</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="792" width="612">
<text top="159" left="57" width="57" height="12" font="1">Validation #2 </text>
<text top="171" left="57" width="34" height="12" font="1">Analysis</text>
<text top="643" left="54" width="145" height="12" font="1">Insert Validation Image (Click here)</text>
<text top="111" left="130" width="425" height="12" font="1">Analysis of Spt5 ChIP-Seq. confirms specificity of ChIP. A 34% of Spt5 ChIP-Seq peaks (p-value &lt; 1e-10) </text>
<text top="123" left="130" width="420" height="12" font="1">are found within 1000bp of a RefSeq transcriptional start site (TSS), consistent with the role of Spt5 in </text>
<text top="135" left="130" width="423" height="12" font="1">blocking RNA polymerase II after early elongation, the majority of peaks are found downstream of the </text>
<text top="147" left="130" width="414" height="12" font="1">TSS. B  Spt5 peaks overlap directly with cognate negative elongation factor, NELFe, and RNAPII, and </text>
<text top="159" left="130" width="404" height="12" font="1">downstream of the general transcription factors TFIIB and TBP. C DSIF (Spt4/Spt5) is known to act </text>
<text top="171" left="130" width="403" height="12" font="1">proximal to the transcriptional start site and travel with elongating RNAPII. Consistent with a role </text>
<text top="183" left="130" width="408" height="12" font="1">downstream of the start site a significant number of Spt5 ChIP-Seq. peaks are found across RefSeq </text>
<text top="195" left="130" width="414" height="12" font="1">genes and proximal to the transcriptional end site, compared to NELFe which associates specifically </text>
<text top="207" left="130" width="127" height="12" font="1">with transcriptional start sites. </text>
<text top="695" left="268" width="68" height="12" font="1">Submit by Email</text>
</page>
</pdf2xml>
